Jupiter Topco LLC Acquires New Shares in Lexeo Therapeutics, Inc. $LXEO

Key Points

• Jupiter Topco LLC acquired 3.95 million Lexeo Therapeutics shares worth approximately $18.4 million, giving it a 5.04% stake. Institutional investors and hedge funds collectively own 60.67% of LXEO.
• Analyst sentiment remains broadly positive, with an average “Buy” rating and a consensus price target of $18.75, although individual views range from “Strong Buy” to “Strong Sell.”
• LXEO opened at $4.86 and remains near its 52-week low after reporting a quarterly loss of $0.30 per share, slightly worse than analyst expectations of a $0.29 loss.

Jupiter Topco LLC acquired a new position in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 3,954,691 shares of the company's stock, valued at approximately $18,409,000. Jupiter Topco LLC owned about 5.04% of Lexeo Therapeutics as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Legal & General Group Plc acquired a new stake in shares of Lexeo Therapeutics during the second quarter valued at about $32,000. Allworth Financial LP grew its holdings in shares of Lexeo Therapeutics by 1,002.9% during the fourth quarter. Allworth Financial LP now owns 3,386 shares of the company's stock worth $34,000 after purchasing an additional 3,079 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in shares of Lexeo Therapeutics in the fourth quarter valued at approximately $37,000. California State Teachers Retirement System raised its holdings in Lexeo Therapeutics by 123.7% in the 4th quarter. California State Teachers Retirement System now owns 3,884 shares of the company's stock valued at $39,000 after buying an additional 2,148 shares during the last quarter. Finally, Cerity Partners LLC bought a new position in Lexeo Therapeutics in the 2nd quarter valued at approximately $50,000. Institutional investors and hedge funds own 60.67% of the company's stock.

Wall Street Analyst Weigh In

LXEO has been the topic of a number of research reports. Chardan Capital raised shares of Lexeo Therapeutics to a "strong-buy" rating in a report on Tuesday, July 28th. Weiss Ratings raised shares of Lexeo Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Thursday, August 13th. Wall Street Zen cut shares of Lexeo Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Saturday, August 15th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Lexeo Therapeutics from $12.00 to $9.00 and set an "overweight" rating on the stock in a research note on Thursday, June 25th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $18.75.

Lexeo Therapeutics Price Performance

Shares of LXEO opened at $4.86 on Friday. The business has a 50-day moving average of $4.74 and a 200-day moving average of $5.46. The company has a market capitalization of $398.74 million, a price-to-earnings ratio of -4.23 and a beta of 1.46. Lexeo Therapeutics, Inc. has a 1 year low of $3.99 and a 1 year high of $10.99.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.01). As a group, sell-side analysts anticipate that Lexeo Therapeutics, Inc. will post -1.18 EPS for the current year.

Insider Buying and Selling

In related news, insider Narinder Pal Bhalla sold 22,306 shares of Lexeo Therapeutics stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $4.42, for a total transaction of $98,592.52. Following the completion of the transaction, the insider owned 82,194 shares of the company's stock, valued at $363,297.48. This trade represents a 21.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Richard Nolan Townsend sold 25,947 shares of the business's stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $4.48, for a total transaction of $116,242.56. Following the completion of the transaction, the chief executive officer owned 377,817 shares in the company, valued at approximately $1,692,620.16. The trade was a 6.43% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 66,326 shares of company stock worth $299,817 in the last 90 days. Corporate insiders own 2.00% of the company's stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source